Kepivance FDA Approval History
FDA Approved: Yes (First approved December 15, 2004)
Brand name: Kepivance
Generic name: palifermin
Dosage form: Injection
Company: Amgen Inc.
Treatment for: Mucositis
Kepivance (palifermin) is a recombinant human keratinocyte growth factor indicated to decrease the incidence and duration of severe oral mucositis.
Development timeline for Kepivance
| Date | Article |
|---|---|
| Dec 15, 2004 | Approval Kepivance Amgen Inc. - Treatment for Severe Oral Mucositis in Cancer Patients |
| Jun 24, 2004 | Amgen Submits Biologics License Application for FDA Approval of Palifermin |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
